NCT06803030 - Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms | Biotech Hunter

Enrollment

189

Participants

Timeline

Start Date

August 30, 2025

Primary Completion Date

December 1, 2025

Study Completion Date

December 31, 2026

Conditions

Ureteral Stent-Related Symptom

Interventions

DRUG

Tamsulosin Hydrochloride 0.4 mg

placement of ureteral stents followed by Cap. Tamsulosin 0.4 mg once daily

DRUG

Solifenacin Succinate 5 mg

placement of ureteral stents followed by Tab. Solifenacin 5 mg once daily

DRUG

Mirabegron 25 mg

placement of ureteral stents followed by Tab. Mirabegron 25 mg once daily

Trial Locations (1)

RECRUITING

NAMS, Bir Hospital, Kathmandu